ADDF In The Media
Last Thursday night I went down to Sotheby’s for a black tie dinner benefiting the Alzheimer’s Drug Discovery Foundation. ADDF was created in 1998 by Leonard and Ronald Lauder, sons of Estee. In the past eight years they’ve established a public profile.
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it raised more than $1.1 million in support of a clinical trial to test an existing drug for the treatment of Alzheimer’s disease. The $1.1 million was generated during the “Fund a Scientist” auction at its Eighth Annual Connoisseur’s Dinner on May 1, 2014, and awarded to Jeffrey Cummings, MD, director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. Dr. Cummings will investigate rasagiline, an FDA-approved treatment for Parkinson’s disease with the potential to be the first drug to slow the course of Alzheimer’s disease.
The ADDF announced today that it raised more than $1.1 million in support of a clinical trial to test an existing drug for the treatment of Alzheimer's disease. The $1.1 million was awarded to Jeffrey Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Cummings will investigate rasagiline, an FDA-approved treatment for Parkinson's disease with the potential to be the first drug to slow the course of Alzheimer's disease.
Moralioglu, who made his inaugural visit to Washington to show his Fall/Winter 2014 collection at the ADDF’s annual Great Ladies Luncheon and Fashion Show, also managed to fit in visits to the Lincoln Memorial, the White House, the POV at the W Hotel and the National Cathedral.
The ADDF, whose “mission is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s,” provides seed funding for early-stage research at Alzheimer’s drug discovery programs around the world. We had the pleasure of speaking with Penny Dacks, Assistant Director of Aging and Alzheimer’s Prevention at the ADDF, about what the foundation does, the challenges they face and some of the exciting new drug research they’re helping make possible.
The Alzheimer’s Drug Discovery Foundation is a biomedical venture philanthropy nonprofit aimed at developing treatments, and eventually a cure, through a diverse portfolio of programs. Many of its grants are structured as investments; the returns are then directed toward new research.
The Lady Vol and winningest coach in NCAA history took time out from March Madness to visit Washington on Tuesday, where she lunched with some of the city’s most fashionable donors. The Alzheimer’s Drug Discovery Foundation honored Summitt, calling her “an inspiration to us all,” for her work with her own foundation, which she founded in 2011 after announcing she had been diagnosed with early-onset Alzheimer’s.
Fisetin, a flavonol found in strawberries, mangoes, cucumber, and other fruits and vegetables, may protect the brain against Alzheimer’s, dementia, and age-related memory loss, according to research just out from the Salk Institute for Biological Studies.
We’ve known for years that the number of deaths caused by Alzheimer’s disease and related dementias have been underreported, but a recent study identified the disease as the potential third-leading cause of death in the U.S. after heart disease and cancer.
As I am on the board of overseers of The Alzheimer's Drug Discovery Foundation, (ADDF) I also follow closely its funding decisions. When I raise money for a charity I want to be able to tell those who give, how their money is being used, and how much of it actually gets to the cause. With ADDF, I can tell them that all of their money goes to research because all overhead is paid for by the Lauder family.